Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Steven D. Heck is active.

Publication


Featured researches published by Steven D. Heck.


Bioorganic & Medicinal Chemistry Letters | 1999

A new class of selective and potent inhibitors of neuronal nitric oxide synthase.

John A. Lowe; Weimin Qian; Robert A. Volkmann; Steven D. Heck; Jolanta Nowakowski; Robert B. Nelson; Charles E. Nolan; Dane Liston; Karen M. Ward; Stevin H. Zorn; Celeste Johnson; Michelle Vanase; W. Stephen Faraci; Kimberly A. Verdries; James Baxter; Shawn D. Doran; Martin Sanders; Mike Ashton; Peter John Whittle; Mark H. Stefaniak

The synthesis and SAR of a series of 6-(4-(substituted)phenyl)-2-aminopyridines as inhibitors of nitric oxide synthase are described. Compound 3a from this series shows potent and selective inhibition of the human nNOS isoform, with pharmacokinetics sufficient to provide in vivo inhibition of nNOS activity.


Bioorganic & Medicinal Chemistry Letters | 2010

Biaryl piperidines as potent and selective delta opioid receptor ligands

Spiros Liras; Stanton Furst Mchardy; Martin Patrick Allen; Barb E. Segelstein; Steven D. Heck; Dianne K. Bryce; Anne W. Schmidt; Michelle Vanase-Frawley; Ernesto Callegari; Stafford McLean

The design and synthesis of novel opiates are reported. Based on the message-address principle a novel class of 4,4- and 3,3-biaryl piperidines was designed and synthesized. Biological evaluation confirmed that these compounds exhibit high affinity and selectivity for the delta opioid receptor. Key structure-activity relationships that influence affinity, selectivity, functional activity and clearance are reported.


Archive | 2002

3-Azabicyclo[3.1.0]hexane derivatives

Stanton Furst Mchardy; Spiros Liras; Steven D. Heck


Bioorganic & Medicinal Chemistry Letters | 2004

Substituted 6-phenyl-pyridin-2-ylamines: selective and potent inhibitors of neuronal nitric oxide synthase.

Deane M. Nason; Steven D. Heck; Mathew S. Bodenstein; John A. Lowe; Robert B. Nelson; Dane Liston; Charles E. Nolan; Lorraine Lanyon; Karen M. Ward; Robert A. Volkmann


MedChemComm | 2011

Discovery of CP-866,087, a mu opioid receptor antagonist for the treatment of alcohol abuse and dependence

Stanton Furst Mchardy; Steven D. Heck; Sara Ann Guediche; Monica Kalman; Martin Patrick Allen; Meihua Tu; Dianne K. Bryce; Anne W. Schmidt; Michelle Vanase-Frawley; Ernesto Callegari; Shawn D. Doran; Nicholas J. Grahame; Stafford McLean; Spiros Liras


Archive | 1993

CALCIUM CHANNEL BLOCKING POLYPEPTIDES FROM FILISTATA HIBERNALIS

Deane M. Nason; Robert T. Ronau; Nicholas Alex Saccomano; Robert A. Volkmann; Steven D. Heck


Synlett | 2000

Shock Sensitivity of a Vinamidinium Bis-Perchlorate Reagent and Demonstration of a Lower Energy Alternative

John A. Ragan; Ruth E. McDermott; Brian P. Jones; David J. am Ende; Pamela J. Clifford; Stanton McHardy; Steven D. Heck; Spiros Liras; Barb E. Segelstein


MedChemComm | 2011

Discovery and pharmacological characterization of a selective delta opiate receptor antagonist (CP-646,777)

Spiros Liras; Stanton Furst Mchardy; Martin Patrick Allen; Barb E. Segelstein; Steven D. Heck; Dianne K. Bryce; Anne W. Schmidt; Rebecca O'connor; Michelle Vanase-Frawley; Ernesto Callegari; Stafford McLean


Archive | 2002

3-azabicyclo[3.1.0]hexan derivative als antagonisten der opioid rezeptoren

Steven D. Heck; Spiros Liras; Stanton F. Pfizer Globa Groton Mchardy


Archive | 2002

Derives 3-azabicyclo (3.1.0) hexane en tant qu'antagonistes de recepteur opioide

Stanton Furst Mchardy; Spiros Liras; Steven D. Heck

Researchain Logo
Decentralizing Knowledge